Health care stocks were lower pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was down 0.3% and iShares Biotechnology ETF (IBB) was recently declining by 0.3%.
Jazz Pharmaceuticals (JAZZ) was down more than 3% after saying its investigational therapy suvecaltamide did not meet its primary endpoint in a phase 2b trial evaluating its efficacy and safety in adult patients with essential tremor.
PTC Therapeutics (PTCT) was up over 3% after saying the US Food and Drug Administration has lifted the partial clinical hold on its PTC518 program following favorable interim results from the phase 2 PIVOT-HD study in Huntington's disease patients.
Cara Therapeutics (CARA) late Tuesday disclosed plans to explore strategic alternatives and lay off 70% of its workforce after discontinuing work on its difelikefalin drug candidate last week for failing to show clinical benefit in pruritus treatment, a nerve disorder. Cara Therapeutics rose past 8% premarket.
Comments